Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Incarceration and Risk of HIV and HCV in PWID

Lancet Infect Dis; ePub 2018 Oct 29; Stone, et al

Incarceration is associated with substantial short-term increases in HIV and hepatitis C virus (HCV) acquisition risk among people who inject drugs (PWID) and may be a significant driver of HCV and HIV transmission among PWID. This according to a systematic review and meta-analysis that aimed to assess whether incarceration history elevates HIV or HCV acquisition among PWID. Published results from 20 studies and unpublished results from 21 studies were included. Researchers found:

  • Recent incarceration was associated with an 81% (relative risk [RR] 1.81) increase in HIV acquisition risk and a 62% (RR 1.62) increase in HCV acquisition risk, with moderate heterogeneity between studies.
  • Past incarceration was associated with a 25% increase in HIV (RR 1.25) and a 21% increase in HCV (RR 1.21).
  • Novel interventions to minimize the risk of HCV and HIV acquisition are needed in this vulnerable population.

Citation:

Stone J, Fraser H, Lim AG, et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: A systematic review and meta-analysis. [Published online ahead of print October 29, 2018]. Lancet Infect Dis. doi:10.1016/ S1473-3099(18)30469-9.